Salphati Laurent, Plise Emile G, Li Guangmin
Drug Metabolism and Pharmacokinetics Department, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
Eur J Pharm Sci. 2009 Jun 28;37(3-4):463-8. doi: 10.1016/j.ejps.2009.04.001. Epub 2009 Apr 9.
The human colorectal carcinoma cell line LS513 exhibits epithelial morphology, adherent properties and can grow subcutaneously to form tumors in nude mice. Thus, it is a potential model for mouse xenograft efficacy studies. The present study characterized the expression and activity of P-gp, BCRP and MRP2 in LS513 cells. We investigated the expression of these ATP-binding cassette transporters by Western blot and their activity was also examined using cell culture inserts, where the LS513 cells were grown to confluence for 9 days. The transport of model substrates of P-gp (amprenavir, ritonavir and topotecan), BCRP (topotecan) and MRP2 (SN-38) was studied in the apical to basolateral (A-B) and basolateral to apical (B-A) directions. P-gp, BCRP and MRP2 could be detected by western blot. The LS513 cells exhibited markedly higher transport in the B-A direction than in the A-B direction for the probe substrates tested, with efflux ratios (ERs; B-A/A-B) of 10, 21, 40 and 50 for amprenavir, ritonavir, topotecan and SN38, respectively. The ER could be significantly reduced with the addition of inhibitors of P-gp (GF120918), BCRP (FTC), and MRP2 (MK571), confirming the activity of these transporters in the LS513 cells.
人结肠癌细胞系LS513呈现上皮形态和贴壁特性,可在裸鼠皮下生长形成肿瘤。因此,它是小鼠异种移植疗效研究的潜在模型。本研究对LS513细胞中P-糖蛋白(P-gp)、乳腺癌耐药蛋白(BCRP)和多药耐药相关蛋白2(MRP2)的表达及活性进行了表征。我们通过蛋白质印迹法研究了这些ATP结合盒转运蛋白的表达,并使用细胞培养插入物检测了它们的活性,其中LS513细胞生长至汇合状态9天。研究了P-gp(安普那韦、利托那韦和拓扑替康)、BCRP(拓扑替康)和MRP2(SN-38)模型底物在顶侧到基底侧(A-B)和基底侧到顶侧(B-A)方向的转运。通过蛋白质印迹法可检测到P-gp、BCRP和MRP2。对于所测试的探针底物,LS513细胞在B-A方向的转运明显高于A-B方向,安普那韦、利托那韦、拓扑替康和SN38的外排率(ERs;B-A/A-B)分别为10、21、40和50。添加P-gp抑制剂(GF120918)、BCRP抑制剂(FTC)和MRP2抑制剂(MK571)后,ER可显著降低,证实了这些转运蛋白在LS513细胞中的活性。